# of Displayed Technologies: 6 / 6

Applied Category Filter (Click To Remove): Oncology


Categories

Self-assembled 3D RNA Cage Nanoparticles with Precise Shape and Size for Applications in Medical Sciences, Materials Sciences, Engineering and Nanotechnology
TS-039545 — Self-assembling, highly stable RNA cages amenable to custom functionalization and cargo delivery
One of the primary challenges in therapeutic development is cheap, efficient, and safe drug delivery to specific target tissues. To better target specific tissues, RNA nanotechnology has been progressively applied to generate predefined architectures via self-assembly of modular building blocks. N…
  • College: College of Pharmacy
  • Inventors: Guo, Peixuan; Jasinski, Daniel; Khisamutdinov, Emil; Li, Hui
  • Licensing Officer: Flammang, Ann Marie

Development of novel furano-parthenolides for human leukemia treatment
TS-038998 — Parthenolide analogues derived from plants could be effective in treating leukemia or supplementing other treatments.
The American Cancer Society estimates that in 2017 there will be about 1,688,780 new cancer cases diagnosed and 600,920 cancer deaths in the United States. Chemotherapy has improved, but further development is needed to improve the efficacy of this treatment, and cancers can develop multidrug resi…
  • College: College of Pharmacy
  • Inventors: Ren, Yulin
  • Licensing Officer: Flammang, Ann Marie

Lipid Nanoparticles for Therapeutic Delivery of Anti-miRs and miRs
TS-037707 — An efficient delivery vehicle for therapeutic oligonucleotides with high efficiency.
The Need MiRNA or miRs are small non-protein coding RNA which are capable of regulating mRNAs in multiple biological pathways, including those involved in cancer development and wound healing. Antagomirs, also known as anti-miRs, inhibit miR activity and could be used to develop therapeutics for in…
  • College: College of Pharmacy
  • Inventors: Lee, Robert
  • Licensing Officer: Flammang, Ann Marie

Novel Use of Fostamatinib as a Therapeutic for Liver Cancer, both as First-Line Therapy and Following Acquired Resistance to Sorafenib
TS-032418 — A combination-therapy that has the potential to overcome and/or prevent the commonly observed acquisition of sorafenib resistance, which is associated with treatment failure in patients with hepatocellular carcinoma.
Hepatocellular carcinoma (HCC) kills nearly all patients within a year of diagnosis, and results in between 250,000 and one million deaths globally per year. In the US, incidences of HCC have nearly tripled in the past 30 years and currently remain one of the fastest growing causes of cancer-relat…
  • College: College of Medicine (COM)
  • Inventors: Motiwala, Tasneem; Regan, Kelly; Reyes, Ryan
  • Licensing Officer: Flammang, Ann Marie

Anti-NCL Immunoagent for Cancer Diagnosis and Therapy
TS-015251 — Nucleolin (NCL) is up-regulated in cancer cells, and modulates pro-tumorigenic pathways and chemoresistance. This anti-NCL agent binds and blocks NCL signaling, and may be optimized as cancer therapeutic and diagnostic tool.
Despite huge advancements in detection and treatment, cancer remains a top world health concern. One of the major limitations of current technology is adequately detecting tumor margins and micrometastases. Even with aggressive tumor resection and adjuvant chemotherapy or radiotherapy, tumor cells…
  • College: College of Medicine (COM)
  • Inventors: Palmieri, Dario; Croce, Carlo; De Lorenzo, Claudia
  • Licensing Officer: Dahlman, Jason "Jay"

Self-Assembly of Camptothecin-Peptide Nanostructures
TS-014812 — An improved delivery mechanism has been developed for camptothecin derivatives which will increase chemotherapeutic efficacy.
Many cancer therapeutics exhibit extremely toxic side effects or have limited efficacy due to low bio-availability. Existing drug delivery technologies can add excessive mass to the therapeutic, grossly expanding the dosage necessary for response. Camptothecin (CPT) is a naturally occurring compou…
  • College: College of Arts & Sciences
  • Inventors: Parquette, Jonathan; Grinstaff, Mark; Kaplan, Jonah; Kim, Se Hye
  • Licensing Officer: Flammang, Ann Marie
PDF

Loading icon